Skip to main content
. 2020 Oct 10;12(19):19421–19439. doi: 10.18632/aging.103841

Table 1. Antibodies employed in this study.

Antibodies Specific Type Dilution Sources
PSD95 Total PSD95 pAb 1/1,000 Cell Signaling
AEP Legumain/Asparaginyl Endopeptidase pAb 1/1000 R&D
SET I2PP2A pAb 1:1000 for WB 1:50 for IP Santa Cruze
PP2Ac PP2AC mAb 1/1000 Millipore
Tau-5 Total-tau mAb 1:1000 for WB Lab Vision
pS199 Phosphorylated Tau at Ser199 pAb 1:1000 for WB Invitrogen
pT231 Phosphorylated Tau at Thr 231 pAb 1:1000 for WB SAB
AT8 Phosphorylated Tau at Ser202/Thr205 mAb 1:1000 for WB Thermo
NR1 C-terminus (amino acids 909-938) mAb 1/500 Millipore
NR2B C-terminus (amino acids 984-1104) pAb 1/500 Millipore
NR2A C terminal last 200 amino acids pAb 1/1,000 Abcam
GluA1 GluA1 protein pAb 1/500 Millipore
GluA2 GluA2 (amino acids 175–430) pAb 1/500 Millipore
Synapsin1 Synapsin 1 pAb 1/1,000 Millipore
Synaptophysin Synaptophysin mAb 1/1,000 Sigma
β-actin β-actin mAb 1/1,000 Abcam
LaminB1 LaminB1 pAb 1/1,000 Abcam

I2PP2A, inhibitor 2 of PP2A; mAb, monoclonal antibody; pAb, polyclonal antibody; WB, Western blot; IP, immunoprecipitation.